4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: January 8, 2024
Period of Report: January 4, 2024
Accession Number: 0001968202-24-000031

View Document ↗ View on SEC.gov ↗